• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The choice of whether to stop or continue ADHD medication during pregnancy and nursing is a difficult decision for women suffering from the condition. There are few data regarding how exposure over time may affect a foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus don't develop neurological disorders such as impaired vision or hearing seizures, febrile seizures or IQ impairment. The authors acknowledge that further high-quality research is needed.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications must weigh the advantages of taking them against potential risks to the foetus. Physicians do not have the data needed to make unequivocal recommendations but they can provide information regarding the risks and benefits to help pregnant women make informed decisions.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during their early pregnancy were not at a greater risk of fetal malformations, or structural birth defects. Researchers used a large sample-based case control study to assess the frequency of major structural defects in infants who were born to mothers who used stimulants during pregnancy. Pediatric cardiologists, clinical geneticists and other experts looked over the cases to ensure that the classification was accurate and to minimize any bias.

The research conducted by the researchers had some limitations. The researchers were not able to, in the first place, to separate the effects triggered by the medication from the disorder. This limitation makes it difficult to determine whether the small differences observed in the exposed groups are due to medication use or comorbidities that cause confusion. The researchers also did not study long-term outcomes for offspring.

The study did show that infants whose mothers took Adhd medication cost uk medication during pregnancy were at a greater risk of being admitted to the neonatal intensive care unit (NICU) than those whose mothers had not taken any medication or cut back on their medications prior to or during pregnancy. The reason for this was central nervous system disorders, and the higher risk of admission did not appear to be affected by the type of stimulant medications were taken during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher risk of having caesarean sections or one whose baby scored low on the Apgar scale (less than 7). These increases didn't appear to be affected by the kind of medication used during pregnancy.

The research suggests that the risk of a small amount with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefit to both mother and child of continued treatment for the woman's disorder. Doctors should discuss with their patients about this issue and as much as possible, assist them develop coping skills that can lessen the impact of her disorder in her daily life and relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and being treated with medication, the question of whether to keep or discontinue treatment during pregnancy is a question that more and more doctors face. These decisions are usually made without clear and authoritative evidence. Instead, physicians must weigh their own knowledge in conjunction with the experiences of other doctors and the research on the topic.

In particular, the issue of potential risks for the baby can be tricky. The research on this subject is based on observation instead of controlled studies and the results are in conflict. Most studies limit their analysis to live births, which may underestimate the severity of teratogenic effects leading to terminations or abortions of pregnancy. The study that is discussed in this journal club addresses these issues by analyzing data on live and deceased births.

The conclusion The conclusion: While certain studies have demonstrated that there is a positive correlation between ADHD medications and the risk of certain birth defects, others have found no connection, and most studies demonstrate a neutral or slightly negative effect. In the end, a careful risk/benefit analysis must be conducted in every instance.

For many women with adhd medications for adults and ADD, the decision to stop medication is difficult, if not impossible. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of loneliness. Additionally, the loss of medication can interfere with the ability to perform job-related tasks and drive safely, which are important aspects of a normal life for many people with ADHD.

She recommends women who are uncertain about whether or not to stop taking best medication for anxiety depression and adhd because of their pregnancy should consider educating family members, friends and colleagues on the condition, its effects on daily functioning, and on the advantages of staying on the current treatment plan. It will also help a woman feel confident about her decision. Certain medications can pass through the placenta. If the patient decides to stop taking her ADHD medication while breastfeeding, it is crucial to be aware that the medication may be transferred to her infant.

Risk of Birth Defects

As the use and use of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD) is increasing the concern over the possible effects of the drugs on fetuses. A recent study published in the journal Molecular Psychiatry adds to the body of knowledge on this subject. Researchers utilized two massive data sets to study over 4.3 million pregnant women and determine whether stimulant medications increased the risk of birth defects. Researchers found that while the risk overall is low, the first trimester ADHD medication exposure was associated with slightly higher risk of certain heart defects, like ventriculoseptal defect.

The researchers of the study could not discover any link between early medication usage and other congenital anomalies, like facial deformities, or club feet. The results are consistent with previous studies revealing the presence of a small, but significant increase in the risk of cardiac malformations in women who started taking ADHD medications prior to the time of the time of pregnancy. The risk increased in the latter stages of pregnancy, when a lot of women decided to stop taking their medication.

Women who took ADHD medication in the first trimester were more likely to need a caesarean, have an insufficient Apgar after delivery and have a baby who needed breathing assistance after birth. The authors of the study were unable to remove bias in selection since they limited the study to women with no other medical conditions that might have contributed to the findings.

The researchers hope that their research will aid in the clinical decisions of doctors who treat pregnant women. The researchers advise that while discussing benefits and risks are important, the choice about whether to continue or stop taking medication should be according to the severity of each woman's ADHD symptoms and her requirements.

The authors also warn that, while stopping the medication is an option, it isn't an option to consider due to the high prevalence of depression and other mental health issues among women who are pregnant or postpartum. Further, the research suggests that women who decide to stop taking their medications are more likely to have a difficult time getting used to life without them after the birth of their baby.

Nursing

It can be overwhelming becoming a mother. Women with ADHD are often faced with a number of difficulties when they must deal with their symptoms, go to doctor appointments and prepare for the birth of a child and adjust to new routines. Many women decide to continue taking their ADHD medication during pregnancy.

The risk to a breastfeeding infant is minimal because the majority of stimulant medication is absorbed through breast milk at low levels. However, the rate of exposure to medication by the newborn can vary depending on dosage, how often it is taken and the time of day it is administered. In addition, individual medications enter the infant's system differently through the gastrointestinal tract as well as breast milk and the impact of this on a newborn isn't fully known.

Some doctors may stop taking stimulant medication during a woman's pregnancy due to the lack of research. This is a complicated decision for the patient, who must weigh the benefits of keeping her medication against the potential risks to the embryo. In the meantime, until more information is available, doctors should ask all pregnant patients about their experience with ADHD and whether they plan or are taking to take medication during the perinatal period.

Numerous studies have demonstrated that women can continue to take their ADHD medication in a safe manner during pregnancy and breast-feeding. In response, a rising number of patients are opting to do so. They have discovered through consultation with their doctor, that the benefits of keeping their current medication outweigh possible risks.

It's important for women with ADHD who are thinking of breastfeeding to seek a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss their medication with their physician and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation is also required to help women with ADHD understand their symptoms and the underlying disorder and learn about treatments and to reinforce existing coping strategies. This should be a multidisciplinary approach including obstetricians, GPs, and psychiatrists. The pregnancy counselling should consist of discussion of a management plan for both the mother and child, as well as monitoring for signs of deterioration, and when necessary, making adjustments to the medication regimen.